Trial Profile

The Effects of Switching From Dolutegravir/Lamivudine/Abacavir (d/l/a) to Bictegravir/Emtricitabine/Tenofovir Alafenamide (b/f/Taf) in Patients With Suppressed Viral Load on Neuropsychiatric Side Effects and Neurocognitive Function

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 16 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary) ; Abacavir/dolutegravir/lamivudine
Indications HIV-1 infections
Focus Adverse reactions
Acronyms DOBINeuro

26 Oct 2022 Results assessing (n=34; at 3 months follow-up) whether the switch to bictegravir/emtricitabine/tenofoviralafenamide arm is associated with a reduction inseverity and incidence of neuropsychiatric symptoms compared tocontinued dolutegravir/abacavir/lamivudine, presented at the 16th International Congress on Drug Therapy and HIV Infection.
29 Jan 2020 Status changed from not yet recruiting to recruiting.
11 Nov 2019 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com